Amneal expands injectables portfolio with 4 new products

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the approval of four generic injectables products. dexamethasone sodium phosphate injection, usp 10 mg/ml, azacitidine 100 mg, carboprost tromethamine injection, usp 250 mcg/ml, and atropine sulfate injection, usp 0.5 mg/5 ml, have received abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda). dexamethasone and azacitidine are bot
AMRX Ratings Summary
AMRX Quant Ranking